Tetanus
Clostridium tetani
stain of tetanus
Tetanus is an acute, often fatal, disease caused by an exotoxin produced by Clostridium tetani. It is characterized by generalized rigidity and convulsive spasms of skeletal muscles. The muscle stiffness usually involves the jaw (lockjaw) and neck and then becomes generalized. Although records from antiquity (5th century B.C.) contain clinical descriptions of tetanus, it was Carle and Rattone who first produced tetanus in animals by injecting them with pus from a fatal human tetanus case in 1884. During the same year, Nicolaier produced tetanus in animals by injecting them with samples of soil. In 1889, Kitasato isolated the organism from a human victim, showed that it produced disease when injected into animals, and reported that the toxin could be neutralized by specific antibodies. In 1897, Nocard demonstrated the protective effect of passively transferred antitoxin, and passive immunization in humans was used during World War I. Tetanus toxoid was developed by Descombey in 1924, and the effectiveness of active immunization was demonstrated in World War II. Clostridium tetani (C. tetani) is a slender, gram-positive, anaerobic rod that may develop a terminal spore, giving it a drumstick appearance. The organism is sensitive to heat and cannot survive in the presence of oxygen. The spores, in contrast, are very resistant to heat and the usual antiseptics. They can survive autoclaving at 121°C for 10-15 minutes. The spores are also relatively resistant to phenol and other chemical agents. The spores are widely distributed in soil and in the intestine and feces of horses, sheep, cattle, dogs, cats, rats, guinea pigs, and chickens. Manure-treated soil may contain large numbers of spores. In agricultural areas, a significant number of human adults may harbor the organism. The spores can also be found on skin surfaces and in contaminated heroin.
Updated Recommendations from the Advisory Committee on Immunization Practices, 2010
Recommendations of the Advisory Committee on Immunization Practices (ACIP) and Recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for Use of Tdap Among Health-Care Personnel
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
National Foundation for Infectious Diseases
Information Paper
Package Insert - Vaccine
Package Insert - Vaccine
Package Insert - Vaccine
Package Insert - Vaccine
Package Insert - Vaccine
Package Insert - Vaccine
Package Insert - Vaccine
GlaxoSmithKline 01 Mar 12
Boostrix
GlaxoSmithKline 14 Apr 09
Pentacel
GlaxoSmithKline 26 Jun 08
Kinrix
MMQC-11-1074 02 Feb 11
UPDATED RECOMMENDATIONS FOR USE OF TETANUS TOXOID, REDUCED DIPHTHERIA TOXOID AND ACELLULAR PERTUSSIS (TDAP) VACCINE FROM THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES, 2010
VIS